Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICIs) have modified the outcome of several advanced malignancies. Thyroid dysfunctions (DYSTHYR) are the most common endocrine immune-related adverse events (IRAEs) during treatment with the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) inhibitors. Data regarding predictive biomarkers enabling stratification of DYSTHYR risk are still limited.Patients and methods: We retrospectively analyzed patien...